Trading Update

AI SummaryClose X

ProBiotix Health plc reported a strong trading performance for the year ended 31 December 2025, with sales increasing by 45% to £2.72 million and gross profit rising by 46% to £1.46 million, leading to a gross profit margin of 54%. The company significantly reduced its EBITDA loss from continuing operations by 31% to £445,000, while maintaining a healthy cash balance of £1.27 million. The first quarter of 2026 shows considerable promise with an order book up 110% to £1.3 million, driven by new customer acquisition and expansion into new markets, including a new menopause-focused product line and entry into Korea.

Disclaimer*

UK 100

Latest directors dealings